ストックスクリーナーアプリを入手
0.6503
4.24%
-0.0288
アフターアワーズ：
.66
0.0097
+1.49%
Context Therapeutics Inc (CNTX) 最新ニュース
CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip - Stocktwits
Small biotech Context Therapeutics reports 29% response rate in ovarian cancer study - MSN
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study - Benzinga
Context Therapeutics Announces Positive Inter - Moomoo
Context Therapeutics rises on interim Phase 1 ovarian cancer data - grafa.com
Context Therapeutics Reports Encouraging Phase 1 Results for CTIM-76 T Cell Engager in Platinum-Resistant Ovarian Cancer – Minichart - Minichart
CNTX: CTIM-76 achieved a 29% response rate and low-grade CRS in heavily pretreated PROC patients - TradingView
Context reports positive interim Phase 1 CTIM-76 data with 29% ORR in PROC, low CRS - TradingView
Context Therapeutics (NASDAQ: CNTX) shows early CTIM-76 activity in platinum-resistant ovarian cancer - Stock Titan
CNTX: CTIM-76 shows 29% response and strong safety in late-line platinum-resistant ovarian cancer - TradingView
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76 - The Manila Times
Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76 - TradingView
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase ... - Caledonian Record
Context Therapeutics Announces Positive Interim Efficacy - GlobeNewswire
Context Therapeutics Grants New-Hire Equity Award Under Nasdaq Rule - MyChesCo
CNTX Q1 2026 Earnings: Narrower Loss Beats Estimates as Context Therapeutics Advances Clinical PipelinePost-Announcement Reaction - newsline.com
Context Therapeutics | 8-K: Current report - Moomoo
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Context Therapeutics (CNTX) - The Globe and Mail
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CNTX Q1 2026 Earnings: EPS Beat Amid Operational Progress; Stock DeclinesEarnings Stability Report - newsline.com
Context Therapeutics (CNTX) Sheds 13.8% as Stock Tests Key Support LevelLow Beta Factor - newsline.com
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
CNTX News | CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) - ChartMill
Piper Sandler Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
- The Legal Advocate
Context Therapeutics (CNTX) Edges Higher, Tests Resistance Near $3.00Impulse Wave - The Legal Advocate
Gyre Therapeutics (GYRE) Gains Momentum: Price Nears Key Resistance at $6.21Equal Weight ETF - The Legal Advocate
Context Therapeutics (CNTX) Holds Near Support as Biotech Sector Faces HeadwindsVolume Rate Change - The Legal Advocate
CNTX Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SurpriseRevenue Estimate Trend - The Legal Advocate
Context Therapeutics Gains 34%, Insider Trades Reap Benefit - 富途牛牛
CNTX Q1 2026 Earnings: Narrower Loss Surprises, Shares Advance Over 13%Estimate Accuracy - The Legal Advocate
Context Therapeutics to Present at the Jefferies Global Healthcare Conference - The Manila Times
Context Therapeutics (CNTX) Surges Over 8% Amid Renewed Buying Interest Above Key SupportGamma Squeeze - The Legal Advocate
Context Therapeutics (CNTX) Gets a Buy from Piper Sandler - The Globe and Mail
CNTX Q1 2026 Earnings: Context Therapeutics Beats EPS Estimates with Narrower-Than-Expected LossGAAP Earnings Report - The Legal Advocate
Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Raises Target Price to $8 - Moomoo
Context Therapeutics Decline Means Insider Profits Down To US$237k - simplywall.st
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - Sahm
Why Is Context Therapeutics Inc. (CNTX) Stock Down Today? - Meyka
Why Is Context Therapeutics Inc. (CNTX) Stock Up Today? - Meyka
Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal - Moomoo
Context Therapeutics Secures Full Rights to CT-202 from BioAtla with License Buyout, Phase 1 Trial Planned for Q3 2026 - Minichart
Context Therapeutics Secures Full Rights to Antibody Assets - TipRanks
Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free - TradingView
Context Therapeutics enters into license agreement amendment with BioAtla for CT-202 - marketscreener.com
Context Therapeutics Inc. Announces Amendment to License Agreement for CT-202, Securing Full Economic Rights - Quiver Quantitative
Context Therapeutics (CNTX) secures fully paid-up, non-terminable CT-202 license - Stock Titan
Context Therapeutics Advances Cancer Drug Pipeline Toward Data Readouts - MyChesCo
Context Therapeutics (CNTX) Slips -6.87%, Testing $2.06 Support 2026-05-15Fast Rising Picks - Newser
Context Therapeutics (CNTX) Crushes Q1 2026 Estimates — EPS $-0.09 Tops ViewsSocial Buy Zones - Newser
Context Therapeutics (CNTX) joint filing shows 2.44% ownership by Great Point Partners - Stock Titan
Blue Owl Capital Holdings (CNTX) Discloses 5.54% Ownership in Context Therapeutics - Stock Titan
Octagon, Master Fund, Ting Jia file 5.25M-share holding in CNTX (5.7%) - Stock Titan
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):